Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.40p -2.38% 139.20p 139.10p 139.20p 141.00p 133.90p 140.70p 1,576,304.00 09:25:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 72.0 -1.9 1.2 116.0 943.24

Vectura Share Discussion Threads

Showing 5626 to 5647 of 5650 messages
Chat Pages: 226  225  224  223  222  221  220  219  218  217  216  215  Older
DateSubjectAuthorDiscuss
25/4/2017
09:25
Soundboy-expected 150-55 if no approval-170-80 if gets it but this will be taken out within a couple of years at much much higher sp, given the dearth of new products big pharma is able to push through the regulatory process (MMyylan) and rapidly expanding upper respiratory market, esp in Asia thanks to pollution and smoking boom. Singer and the likes are well aware of this and thus want cheap shares. I'll be adding at different target levels for meduium long term-only way to make anything on pharma. imo
cumnor
25/4/2017
08:25
Soundbuy-yes, I'd been expecting a fall to these levels if May 10th had brought bad news. In the couple of months from end of Jan the share price had risen steadily from 130 to over 160. In the month since the Mylan announcement it has lost most of those gains. I never realised how much the share price depended upon generic Advair approval. The Singer report is a complete about-face as they seem to be negative even if VEC get Advair approval. I'd like to see updates from some of the other broker/analysts.
alexchry
25/4/2017
08:11
This is where I expected the share to be if approval not given.....grrrrrrr
soundbuy
25/4/2017
08:07
Note and associated commentary doing the damage.......
soundbuy
25/4/2017
07:50
Couldn't have said it better myself Cumnor - smoke and mirrors designed to screw the minnows
richtea1701
24/4/2017
23:27
Cumnor, don't normally go for the conspiracy theory, but this is fishy. Let's see if any other brokers spot the obvious demise in the prospects here.
diesel
24/4/2017
22:17
How much is Hikma's approval actually worth to Vectura? The FT is reporting that Singer are suggesting a Vectura share price of £1.55 upon approval or £1.07 for an absolute rejection. Does anyone know what the actual affect on the company's bottom line is projected to be? Surely it can't be worth 30% of the company?
popper joe
24/4/2017
20:36
Still remain reasonably confident that Hikma will get the thumbs up on May 10th. Trump's on record when it comes to support for less expensive generic counterparts and a pound to a penny that Hikma have covered all angles prior to submission. Still reckon Mylan's failure part political.
carpadium
24/4/2017
17:12
This is a Snakes and ladders share........very hard climb BUT very easy slide back down! Considering selling as I feel I have missed many others whilst waiting for VEC to break the 200 mark...
jopper74
24/4/2017
14:51
Annual report:http://www.vectura.com/files/7314/9277/1782/Vectura_Group_plc_Report_and_Accounts_for_the_nine-month_period_ended_31_December_2016.pdf
dontay
24/4/2017
13:39
Exactly ace
gswredland
24/4/2017
12:51
A one third target price reduction looks a bit ridiculous on the likelihood of something getting marketing approval!
aceuk
24/4/2017
12:38
Unless some information has leaked out regarding Mylan's rejection or Hikma's application then Singer or any other broker/analyst is just guessing. What I can't understand is why Singer didn't issue this note soon after the Mylan decision was known.
alexchry
24/4/2017
12:08
All eyes on whether or not other broker forecasts change for the worse. If they don't then it would appear N+1 Singer being singularly ultra-cautious. Fully agree with diesel's 5544.
carpadium
24/4/2017
11:33
This all looks rather odd, brokers do not normally do such a dramatic turnabout unless something truly disastrous has happened.
diesel
24/4/2017
10:16
One wonders if recent weakness was Singers' clients duly departing.......
soundbuy
24/4/2017
10:11
my when this goes it goes!!!!!!!!!!!!!!!!!
pooroldboy55
24/4/2017
10:05
You can see why shorting is so effective, so much easier to get a negative effect than a positive one! How long have we seen all the broker targets north of 200 yet one broker downgrades and whoosh...not even sure that the success of 315 is factored in at these levels.
diesel
24/4/2017
09:35
Soundbuy-depends what happens on May 10th as to whether it was a brave call or a prudent one. The market seems to be betting on prudence, VEC were over 160p when Mylan got the knock back so even without the Singer sell note the share price has been weak.
alexchry
24/4/2017
09:31
'Following a review of product-level forecasts, we have reduced FY2017-18e revenue forecasts by 6.6% & 10.9% respectively. Following Mylan’s generic Advair® setback, we have also downgraded the likelihood of success for VR315 in the US. Although we remain impressed by the depth of Vectura’s pipeline, the potential valuation upside does not currently outweigh the risk of VR315 non-approval or delayed approval. We downgrade to Sell ahead of the 10th May GDUFA date with a TP of 131p (from 202p). '
soundbuy
24/4/2017
09:27
Prudent? Perhaps.... Rather a brave call on their part....
soundbuy
24/4/2017
09:15
When the Mylan advair generic got a knock back, it was only to be expected that there would be a shadow of over Vectura's generic. At the moment we don't know whether the issue concerning Mylan's generic is specific to them or has raised the bar for everyone. It's possible there has been a leakage of information but it may just be that Singer are taking a prudent view and hence the sell recommendation. I'm hanging on until May 10th, I might live to regret it but I'm hoping that at last we'll have some good news.
alexchry
Chat Pages: 226  225  224  223  222  221  220  219  218  217  216  215  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170425 08:40:56